文献速递烧伤

静脉铁剂治疗烧伤贫血:一项回顾性队列研究

Intravenous iron therapy to treat burn anaemia: A retrospective cohort study.
PubMed 文献 · Burns · 2022-05-23

该回顾性队列研究纳入皇家布里斯班妇女医院烧伤面积至少15%总体表面积(TBSA)的患者60例,其中11例(18%)接受静脉铁剂治疗。静脉铁剂组烧伤面积更大(中位数39% vs 18%,P=0.0005)、手术次数更多(3次 vs 1次,P=0.0012)、输血量更多(中位数8单位 vs 0单位,P=0.0002)。末次大手术后前14天,静脉铁剂组 modelled 血红蛋白变化为11.22 g/L,较未接受静脉铁剂组的-3.34 g/L高14.56 g/L(P=0.0282)。该探索性研究提供了静脉铁剂治疗烧伤贫血恢复获益与安全性的初步证据。

要点

  • 静脉铁剂组烧伤面积更大(中位数39% vs 18%,P=0.0005)、手术次数更多(3次 vs 1次,P=0.0012)、输血量更多(中位数8单位 vs 0单位,P=0.0002)。
  • 1例(9%)发生轻度药物不良反应。
  • 末次大手术后前14天,静脉铁剂组 modelled 血红蛋白变化较未接受静脉铁剂组高14.56 g/L(11.22 g/L vs -3.34 g/L,P=0.0282)。

核心结论

  • 该探索性研究提供了静脉铁剂治疗对烧伤贫血恢复获益与安全性的初步证据。

研究设计与样本

  • 回顾性队列研究,纳入皇家布里斯班妇女医院烧伤面积至少15%总体表面积(TBSA)的患者60例,其中11例(18%)接受静脉铁剂治疗。
  • 采用线性混合效应回归模型评估静脉铁剂治疗对血红蛋白随时间变化的影响。

主要发现

  • 静脉铁剂组与未接受静脉铁剂组相比:烧伤面积中位数39% vs 18%(P=0.0005),手术次数3次 vs 1次(P=0.0012),输血量中位数8单位 vs 0单位(P=0.0002)。
  • 1例(9%)接受静脉铁剂治疗的患者发生轻度药物不良反应。
  • 末次大手术后前14天,静脉铁剂组 modelled 血红蛋白变化为11.22 g/L,未接受静脉铁剂组为-3.34 g/L,静脉铁剂组较未接受静脉铁剂组高14.56 g/L(P=0.0282)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intravenous iron is an effective treatment for anaemia in many populations but has not been evaluated in those with burn anaemia. This study aimed to evaluate the efficacy and safety of intravenous iron to manage burn anaemia. METHODOLOGY: This was a retrospective cohort study of patients admitted to the Royal Brisbane and Women's Hospital with burns to at least 15% total body surface area (TBSA). Data collected from patient records included demographics, treatment details, and outcomes including length of stay, blood transfusions, and serum haemoglobin concentrations. Linear mixed effects regression models were used to assess the effect of treatment with intravenous iron on haemoglobin over time. RESULTS: Sixty patients met inclusion criteria, with 11 (18%) treated using intravenous iron. Those treated with intravenous iron had higher TBSA burns (median 39% vs 18%, P = 0.0005), more operations (3 vs 1, P = 0.0012), and more blood transfusions (median 8 units vs 0 units, P = 0.0002). One patient (9%) experienced a minor adverse drug reaction from intravenous iron. When examining the change in modelled haemoglobin levels over the first 14 days following the last major operation, the change in the intravenous iron group (11.22 g/L) was 14.56 g/L greater than the change in the group not receiving intravenous iron (-3.34 g/L, P = 0.0282). CONCLUSION: This exploratory study provides preliminary evidence of benefit and safety of intravenous iron treatment on burn anaemia recovery.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Betar N, Warren J, Adams J, et al. Intravenous iron therapy to treat burn anaemia: A retrospective cohort study. Burns. 2022. PMID: 35717364. doi:10.1016/j.burns.2022.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。